Genomics

Dataset Information

0

RAD51 ChIP-seq post treatment with CX-5461


ABSTRACT: We discovered two small molecule drugs - CX-5461 and CX-3543 - with specific toxicity against BRCA deficiencies in cancer cells and xenograft models. Both CX-5461 and CX-3543 have been previously recognized as RNA pol I inhibitors. CX-5461 is in advanced phase 1 trials for treatment of lymphoma and leukemia through rDNA transcription inhibition in a p53-dependent mechanism. We have discovered a novel activity of CX-5461, as a stabilizer of G-quadruplex DNA sequences inside cells the same as CX-3543. We found that BRCA1 and BRCA2 deficiency markedly increases (one log order) sensitivity to CX-5461 and a related drug CX-3543 in human cancer cell lines and polyclonal patient derived xenograft models, providing a direct therapeutic hypothesis, including PDX tumours resistant to PARP inhibition. We show that in epithelial cells, exposure to CX-5461 and CX-3543 blocks replication forks and induces ssDNA gaps or breaks. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543 induced DNA damage and failure to do so leads to lethality. RNA pol I inhibition is not a required component of the cell killing mechanism in these tumours, because BRCA2 deficient cells are not more sensitive to BMH-21, a more potent rDNA transcription inhibitor. These data strengthen the concept of G4 targeting as a therapeutic approach, specifically for targeting HR and NHEJ deficient cancers and other tumors deficient for DNA damage repair. Since CX-5461 is already in advanced phase 1 trials for other indications, this has resulted in immediately testable translational implications (Canadian trial, NCT02719977, opened May 2016) as no phase-1 eligible G4 stabilizers have been described to date.

ORGANISM(S): Homo sapiens

PROVIDER: GSE90967 | GEO | 2016/12/06

SECONDARY ACCESSION(S): PRJNA356460

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-04-07 | E-MTAB-9242 | biostudies-arrayexpress
2024-03-18 | GSE261563 | GEO
| EGAS00001006173 | EGA
2024-03-18 | GSE261562 | GEO
2024-01-02 | GSE235142 | GEO
2022-12-21 | GSE201899 | GEO
2019-08-26 | GSE118565 | GEO
2023-02-12 | PXD038439 | Pride
2024-02-15 | GSE255898 | GEO
2022-06-07 | GSE200919 | GEO